Compliance Corner January 2026
Mark your calendar for the next BPHC Program Updates webcast. The Bureau will share access information in the next Primary Health Care Digest.
Thursday, January 29
2:00 – 3:00 p.m. ET
Join by phone: 833 568 8864
Webinar ID: 160 759 7067; Passcode: 24803634
Source: BPHC
HRSA is issuing updated terms on health centers’ compliance with applicable state or federal laws regarding parental consent. These updated terms will apply to all HRSA-funded health centers and Health Center Program look-alikes. Please review your Notice of Award or your Notice of Look-Alike Designation.
Source: BPHC
HRSA has updated the Health Center Program Site Visit Protocol (SVP) to align with current program guidance, including the recently updated HHS Grants Policies and Regulations. Review the summary of updates.
If you have questions about your upcoming OSV, please contact your Federal site visit representative. For general questions about the protocol, use the BPHC Contact Form (Policy > Site Visit Protocol General Inquiry).
Source: HRSA
The 2025 UDS reporting period started on Thursday, January 1. All Health Center Program awardees and look-alikes are required to submit UDS reports by 11:59 p.m. local time on Sunday, February 15.
Visit the UDS Technical Assistance (TA) webpages to access the 2025 UDS Manual and other resources to help health centers submit accurate, timely, and complete UDS reports for this calendar year.
If you need additional assistance, please use these resources:
Source: HRSA
In accordance with the December 29, 2025, U.S. District Court for the District of Maine order in American Hospital Association et al. v. Kennedy et al., No. 25-cv-600 (D. Me.) and the subsequent January 7, 2026, U.S. Circuit Court of Appeals for the First Circuit order in American Hospital Association et al. v. Kennedy et al., No. 25-2236 (1st Cir.), HRSA’s Office of Pharmacy Affairs (OPA) is pausing the implementation of the 340B Rebate Model Pilot Program for all covered entity types at this time. Manufacturers who were approved for participation in the Pilot to effectuate 340B pricing through a rebate mechanism will now be required to continue to offer all of their covered outpatient drugs to 340B covered entities at the 340B ceiling price as an up-front discount. OPA will update stakeholders on developments regarding the Pilot as they arise.
Source: HRSA
Compliance was never meant to feel this heavy. But for many healthcare organizations, it has become exactly that.
Requirements keep expanding. Oversight is more intense. Audits are more frequent. And too often, the work is still managed through disconnected systems, spreadsheets, and constant manual follow-ups.
There is a better way to do this work.